Advertisement
Advertisement
TOPIC

Biomedicine: Industry Trends

Related Topics:
Biomedicine: Industry Trends
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
China is attempting to boost the sales of at least five of its drugs to US$1 billion by 2030. Photo: Shutterstock
China’s private sector

China wants 5 innovative drugs with US$1b returns by 2030. Which might they be?

Beijing is attempting to have at least five pharmaceutical products with annual global sales of more than US$1 billion.

videocam
Biomedicine: Companies

Chinese biotech faces reality check as ArriVent drug failure sinks stock in US

Biomedicine: Policy

Hong Kong needs new funding model to attract global drug makers: AstraZeneca

videocam
China technology

Chinese biopharma’s global expansion

Chinese developers of innovative drugs are tying up with industry giants to accelerate overseas growth, raise funds and share risks.

Chinese biopharma’s global expansion
Biomedicine: Companies

AstraZeneca, Merck, Novo deals inject fresh global momentum into Chinese biotech

Deals involving novel cancer therapies and weight-loss drugs reinforce the growing global appeal of Chinese biotech innovation.

Mainland China

How Chinese biotech is graduating from licensing deals to broader partnerships

InnoCare’s pact with Eli Lilly, potentially worth up to US$3.35 billion, highlights a shift towards bigger partnerships, analysts say.

Advertisement
Advertisement
Advertisement
China technology

Are clinical trials about to become a new front in the US-China biotech race?

China’s ability to conduct clinical trials quickly and cheaply has given it an edge in the biotech sector – and the US is growing concerned.

A sign for the Food And Drug Administration outside its headquarters in Maryland. Photo: Getty Images
Hong Kong stock market

‘High tide’ of China biotech deals seen as US curb fears fade: analysts

Stocks jump on reports Washington will allow most licensing deals under ‘substantially softer stance’ than had been feared, analysts say.

videocam
China economy

China’s five-year plan for pharmaceuticals and biomedicine

China aims to become a global drug powerhouse by 2030, according to its five-year development plan for the pharmaceutical and biomedicine sector.

Biomedicine: Policy

Can targeted sound waves transform treatment for pancreatic and brain cancers?

A leading advocate says global trials in pancreatic and brain cancers may yield results within 3 years, with Alzheimer’s another application.

Focused ultrasound is being studied as a non-invasive way to target brain tumours including glioblastoma, an aggressive form of the disease. Photo: Shutterstock
Biomedicine: Policy

Biomedicine powerhouse: China targets quarter of global first-in-class drugs

New five-year plan aims to turn the sector into a pillar industry by 2030, driven by breakthroughs in technologies across critical fields.

The plan sets 10 targets, including requiring large pharmaceutical enterprises to generate combined revenue of no less than 3.5 trillion yuan. Photo: Shutterstock
Biomedicine: Companies

ByteDance spin-off Anew Labs raises US$290m amid AI drug design fundraising boom

As AI’s role in drug design advances rapidly, Chinese start-ups are ramping up fundraising efforts.

videocam
Biomedicine: Companies

GSK’s US$750 million cancer drug deal highlights China’s rise as biotech player

The acquisition is the latest in a string of major licensing deals involving Chinese biotechnology firms.

4
Greater Bay Area

Data from Greater Bay Area residents to help improve healthcare policy: GSK

Executive says pharmaceutical company is investing in shared data infrastructure.

GSK’s general manager for Hong Kong and Macau, Nicholas Teo, at the Hong Kong International Biotechnology Conference and Exhibition on Thursday. Photo: Jonathan Wong
Yuan

Open Questions | Private equity’s Fang Fenglei on investing in China

Veteran investor considers China’s economic strengths, assets that appeal, future yuan appreciation and policymakers’ ability to solve problems.

videocam
Illustration: Brian Wang
Greater Bay Area

Hong Kong targets biomedicine powerhouse status in debut 5-year plan

Tied to the national strategy, the city’s first five-year blueprint doubles down on Greater Bay Area medical tech and healthcare cooperation.

China’s private sector

China needs monkeys: lab animal shortage could hinder biotech growth

As fundraising and out-licensing deals in China grow, so does demand for monkeys and other primates for testing.

Advertisement
Advertisement
Advertisement
Science

US, China trials suggest a single nanodrug shot might stop bad cholesterol forever

Separate trials using CRISPR and base editing to silence lipid genes show drastic drops in LDL-C without daily medication.

videocam
Two breakthrough clinical trials suggest that patients with high cholesterol may one day benefit from a one-and-done injection to keep bad cholesterol under control. Photo: Shutterstock Images
IPO

More Chinese developers of brain-computer interfaces move towards IPOs

Arfysica and Neuracle aim for Star Market listings amid what a Morgan Stanley analyst calls the ‘early stage of a multi-year IPO upcycle’.

videocam
China technology

China approves string of ‘telepathy’ devices amid push to leapfrog Elon Musk

Chinese regulators have approved a group of brain-technology products this year, as local start-ups push to surpass Musk’s Neuralink.

Banking & finance

Why Asian investors are pouring capital into brain tech and surgical robots

Family offices and venture investors across Hong Kong and the wider region are reshaping portfolios to capture long-term biotech growth.

An orthopedic surgical robot is displayed at the 2026 World Robot Conference in Beijing on August 20. Photo: Xinhua
Banking & finance

US surgical robotics firm targets Hong Kong listing to tap mainland China market

Noah Medical expects to file application as early as next year, joining surge of tech listings tapping city’s international fundraising pool.

videocam
Noah Medical has begun preparations for a Hong Kong listing. Photo: Handout
Hong Kong stock market

China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial

The biliary tract cancer trial is the latest breakthrough for Akeso’s ivonescimab, which has also shown promise in treating some lung cancers.

Robotics

Brain-tech push gains pace as China sets standards and firms challenge Neuralink

Dozens of guidelines are coming, covering medical, industrial and consumer users as emerging neural technology moves towards wider adoption.

4
Hong Kong stock market

China rushes to develop Moderna-style cancer vaccines amid market frenzy

Chinese biotech firms are already working on more than 100 cancer vaccines. Now, many are seeing their shares surge amid Moderna’s breakthrough.

videocam
7
Chinese biotechnology firms are working on more than 100 cancer vaccine programmes, according to analysts. Photo: Shutterstock
Wuxi Biologics

WuXi Biologics posts 4.3% rise in first-half profit, defying biotech headwinds

Higher gross margins, surging projects and continued demand from North American markets help power the drug developer’s strong first-half performance.

Wuxi Biologics is a pharmaceutical research and services company based in Wuxi, Jiangsu province, China. Photo: Shutterstock
Medicine

Overseas licensing has helped fuel China’s biotech profits. Will it last?

Out-licensing deals have overtaken IPOs as the primary lifeline for cash-starved Chinese drug makers, analysts say.

videocam
Science

Chinese stem cell therapy restores heart function in 90% of trial patients

Study finds patients injected with iPSC-derived heart muscle cells outperform control group on cardiac function tests after bypass surgery.

videocam
12
Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement